Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
JCO Precis Oncol. 2023 May;7:e2200557. doi: 10.1200/PO.22.00557.
Analysis of somatic variant profiles in retrospectively collected pairs of primary tumors and synchronous liver metastases from surgically treated patients with colorectal carcinomas. Mutational profiles were compared between groups of patients stratified by response to chemotherapy and survival.
The study used whole-exome sequencing of tumor sample pairs from 20 patients diagnosed and treated at a single center. The Cancer Genome Atlas COAD-READ data set (n = 380) was used for validation in silico, where possible.
The most frequently altered oncodrivers were (55% in primaries and 60% in metastases), (50/45), (30/5), (20/25), and (15/25). Harboring variants with a high or moderate predicted functional effect in in primary tumors was significantly associated with poor relapse-free survival in both our sample set and the validation data set. We found a number of additional prognostic associations, including mutational load, alterations in individual genes, oncodriver pathways, and single base substitution (SBS) signatures in primary tissues, which were not confirmed by validation. Altered , , and , or a higher share of SBS24 signature in metastases seemed to represent poor prognostic factors, but because of a lack of suitable validation data sets, these results must be treated with extreme caution. No gene or profile was significantly associated with response to chemotherapy.
Taken together, we report subtle differences in exome mutational profiles between paired primary tumors and synchronous liver metastases and a distinct prognostic relevance of in primary tumors. Although the general scarcity of primary tumor-synchronous metastasis sample pairs with high-quality clinical data makes robust validation difficult, this study provides potentially valuable data for utilization in precision oncology and could serve as a springboard for larger studies.
分析经手术治疗的结直肠癌患者的原发性肿瘤和同步肝转移灶配对标本中体细胞变异谱。对化疗反应和生存情况分层的患者组之间的突变谱进行了比较。
本研究使用了 20 名在单一中心确诊和治疗的患者的肿瘤样本对进行全外显子组测序。尽可能地在癌症基因组图谱 COAD-READ 数据集(n=380)中进行了验证。
最常改变的致癌驱动因素是 (55%在原发性肿瘤和 60%在转移灶)、 (50/45)、 (30/5)、 (20/25)和 (15/25)。原发性肿瘤中存在高或中度预测功能效应的变异与我们的样本集和验证数据集的无复发生存率显著相关。我们发现了一些其他的预后关联,包括突变负荷、个别基因的改变、致癌驱动途径和原发性组织中的单碱基取代(SBS)特征,这些在验证中并未得到确认。转移灶中改变的 、 、 ,或 SBS24 特征的比例较高,似乎代表了不良的预后因素,但由于缺乏合适的验证数据集,这些结果必须谨慎处理。没有基因或特征与化疗反应显著相关。
总的来说,我们报告了配对原发性肿瘤和同步肝转移灶之间外显子突变谱的细微差异,以及原发性肿瘤中 显著的预后相关性。尽管具有高质量临床数据的原发性肿瘤-同步转移灶样本对的一般稀缺性使得稳健验证变得困难,但本研究为精准肿瘤学提供了有潜在价值的数据,并可能成为更大规模研究的起点。